Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 5, 2014, Pages 295-302

  Erem, C ^a   Ozbas, H M ^a   Nuhoglu, I ^a   Deger, O ^b   Civan, N ^a   Ersoz, H O ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b Trabzon Endocrinological Studies Group   (Turkey)

Author keywords

cardiovascular risk factors; gliclazide MR; glycemic control; metformin; pioglitazone; type 2 diabetes

Indexed keywords

ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLICLAZIDE; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; METFORMIN; PIOGLITAZONE; VON WILLEBRAND FACTOR; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OPTIMAL DRUG DOSE; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; AGED; BLOOD; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; RISK FACTOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLICLAZIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 84901021383     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0034-1370989     Document Type: Article

References (48)

1. Haffner S. M., Greenberg A. S., Weston W. M. et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation: 2002; 106 679 684 (Pubitemid 34851926)
2. Lund S. S., Tarnow L., Stehouwer C. D. et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol: 2008; 158 631 641 (Pubitemid 351639600)
3. Fidan E., Onder Ersoz H., Yilmaz M. et al. The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus. Acta Diabetol: 2011; 48 297 302
4. Erem C., Hacihasanoǧlu A., Celik S. et al. Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications. Med Princ Pract: 2005; 14 22 30
5. Pavo I., Jermendy G., Varkonyi T. T. et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism: 2003; 88 1637 1645 (Pubitemid 36623381)
6. Vilar L., Canadas V., Arruda M. J. et al. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arq Bras Endocrinol Metabol: 2010; 54 311 318
7. Levetan C. Oral antidiabetic agents in type 2 diabetes. Curr Med Res Opin: 2007; 23 945 952 (Pubitemid 46631497)
8. Drouin P., Standl E. Diamicron MR Study Group Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes. Diabetes Obes Metab: 2004; 6 414 421 (Pubitemid 39409792)
9. Khanolkar M. P., Morris R. H., Thomas A. W. et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus - an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis: 2008; 197 718 724 (Pubitemid 351417869)
10. Kim H. J., Kang E. S., Kim D. J. et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxf): 2007; 66 282 289 (Pubitemid 46096150)
11. Matthews D. R., Charbonnel B. H., Hanefeld M. et al. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev: 2005; 21 167 174 (Pubitemid 40467663)
12. Betteridge D. J., Vergès B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes. Diabetologia: 2005; 48 2477 2481 (Pubitemid 41738210)
13. Tan M. H. Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl: 2000; 54 62
14. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care: 2010; 33 01 S62 S69
15. Taniguchi A., Fukushima M., Sakai M. et al. Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care: 2000; 23 1766 1769
16. McAuley K. A., Williams S. M., Mann J. I. et al. Diagnosing insulin resistance in the general population. Diabetes Care: 2001; 24 460 464 (Pubitemid 32198413)
17. Friedewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem: 1972; 18 499 502
18. Rodbard H. W., Blonde L., Braithwaite S. S. et al. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract: 2007; 13 01 1 68
19. Yener S., Comlekci A., Akinci B. et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Medical Principles and Practice: 2009; 18 266 271
20. Belcher L., Lambert C., Edwards G. et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Research and Clinical Practice: 2005; 70 53 62 (Pubitemid 41207648)
21. Derosa G., Cicero A. F., Gaddi A. et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract: 2005; 69 5 13 (Pubitemid 40813407)
22. Kahn S. E., Haffner S. M., Heise M. A. et al. ADOPT Study Group Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med: 2006; 355 2427 2443 (Pubitemid 44903747)
23. Hanefeld M. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. Int J Clin Pract Suppl: 2007; 61 (Suppl. 153) 20 27 (Pubitemid 47000686)
24. Tan M. H., Baksi A., Krahulec B. et al. GLAL Study Group Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care: 2005; 28 544 550 (Pubitemid 40315311)
25. Perriello G., Pampanelli S., Di Pietro C. et al. Italian Pioglitazone Study Group Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabet Med: 2006; 23 246 252
26. Kato T., Sawai Y., Kanayama H. et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes: 2009; 117 593 599
27. Charbonnel B. H., Matthews D. R., Schernthaner G. et al. QUARTET Study Group A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med: 2005; 22 399 405 (Pubitemid 40516237)
28. Fukuzawa M., Satoh J., Qiang X. et al. Inhibition of tumor necrosis factor-alpha with anti-diabetic agents. Diabetes Res Clin Pract: 1999; 43 147 154 (Pubitemid 29202124)
29. Cathelineau G., de Champvallins M., Bouallouche A. et al. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment - the Diadem Study. Metabolism: 1997; 46 01 31 34
30. Chen K. W., Juang J. H., Huang H. S. et al. Effect of gliclazide on plasma lipids and pancreatic beta cell function in non-insulin-dependent diabetes mellitus. Changgeng Yi Xue Za Zhi: 1993; 16 246 250
31. Scarpello J. H., Howlett H. C. Metformin therapy and clinical uses. Diab Vasc Dis Res: 2008; 5 157 167
32. Perez A., Khan M., Johnson T. et al. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res: 2004; 1 44 50
33. Spanheimer R., Betteridge D. J., Tan M. H. et al. PROactive Investigators Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol: 2009; 104 234 239
34. Tessier D., Maheux P., Khalil A. et al. Effects of gliclazide versus metformin on the clinical profile and lipid peroxidation markers in type 2 diabetes. Metabolism: 1999; 48 897 903 (Pubitemid 29310047)
35. Kassem S. A., Raz I. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care: 2009; 32 02 S337 S341
36. Drzewoski J., Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Current Medical Research and Opinion: 2006; 22 1921 1926 (Pubitemid 44663396)
37. De Jager J., Kooy A., Lehert P. et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med: 2005; 257 100 109 (Pubitemid 40129131)
38. You S. H., Kim B. S., Hong S. J. et al. The effects of pioglitazone in reducing atherosclerosis progression and neointima volume in type 2 diabetic patients: prospective randomized study with volumetric intravascular ultrasonography analysis. Korean Circ J: 2010; 40 625 631
39. Sacks H. S., Fain J. N., Cheema P. et al. Inflammatory genes in epicardial fat contiguous with coronary atherosclerosis in the metabolic syndrome and type 2 diabetes: changes associated with pioglitazone. Diabetes Care: 2011; 34 730 733
40. Albertini J. P., McMorn S. O., Chen H. et al. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. Atherosclerosis: 2007; 195 e159 e166 (Pubitemid 47569985)
41. Itoh M., Omi H., Okouchi M. et al. The mechanisms of inhibitory actions of gliclazide on neutrophils-endothelial cells adhesion and surface expression of endothelial adhesion molecules mediated by a high glucose concentration. J Diabetes Complications: 2003; 17 22 26 (Pubitemid 36042788)
42. Räkel A., Renier G., Roussin A. et al. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. Diabetes Obes Metab: 2007; 9 127 129 (Pubitemid 44921051)
43. Derosa G., Cicero A. F., D'Angelo A. et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther: 2006; 28 679 688 (Pubitemid 44067262)
44. Ryan K. E., McCance D. R., Powell L. et al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis: 2007; 194 e123 e130 (Pubitemid 47513101)
45. Schöndorf T., Musholt P. B., Hohberg C. et al. The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study. J Diabetes Sci Technol: 2011; 5 426 432
46. Sahin M., Tutuncu N. B., Ertugrul D. et al. Effects of metformin or rosiglitazone on serum concentrations of homocysteine, folate, and vitamin B12 in patients with type 2 diabetes mellitus. J Diabetes Complications: 2007; 21 118 123
47. Derosa G., D'Angelo A., Ragonesi P. D. et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther: 2006; 31 375 383 (Pubitemid 44060202)
48. Munshi M. N., Stone A., Fink L. et al. Hyperhomocysteinemia following a methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism: 1996; 45 133 135 (Pubitemid 26104279)